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Abstract
Anaplastic thyroid carcinoma (ATC) is one of the most
aggressive human malignancies with a mean survival of
only 6 months. The poor prognosis of patients with ATC
reflects the current lack of curative therapeutic options
and the need for development of novel therapeutic
strategies. In this study, we report the results of a
preclinical study of AEE788, a dual inhibitor of epidermal
growth factor receptor (EGFR) and vascular endothelial
growth factor receptor (VEGFR) tyrosine kinases, against
ATC. AEE788 was able to inhibit the proliferation and
induce apoptosis of ATC cell lines in vitro. Administration
of AEE788, alone and in combination with paclitaxel, to
athymic nude mice bearing s.c. ATC xenografts inhibited
the growth of ATC xenografts by 44% and 69%,
respectively, compared with the control group. Further-
more, tumors from mice treated with AEE788, alone and
in combination with paclitaxel, showed increase in
apoptosis of tumor cells by f6- and 8-fold, respectively,
compared with the control group. The microvessel density
within the ATC xenografts was decreased by >80% in
the mice treated with AEE788 alone and in combination
with paclitaxel compared with the control group. Lastly,
immunofluorescence microscopy showed the inhibition of
EGFR autophosphorylation on the tumor cells as well as
the inhibition of VEGFR-2 autophosphorylation on tumor
endothelium. Considering the fact that curative options
seldom exist for patients with ATC, concurrent inhibition
of EGFR and VEGFR tyrosine kinases seems to be a valid
and promising anticancer strategy for these patients. [Mol
Cancer Ther 2005;4(4):632–40]
Introduction
Carcinomas of the thyroid gland account for f1% of all
new malignant diseases in the United States (1). Relatively
high cure rates can be achieved in well-differentiated
thyroid carcinomas, such as papillary and follicular thyroid
carcinomas. However, anaplastic thyroid carcinoma (ATC)
is one of the most aggressive human malignancies known
and carries a grave prognosis (2). Although ATC accounts
for only 1.6% of all thyroid cancers, the median overall
survival following diagnosis is only 6 months (3, 4). The
disease is usually well advanced by the time of diagnosis as
evidenced by the average presenting tumor size of f8 cm.
Ninety percent of the patients have extraglandular spread
at the time of diagnosis and 75% of the patients develop
distant metastasis (5, 6). Because ATC is such an aggressive
disease, it is staged by the American Joint Commission on
Cancer as stage IV regardless of tumor size, cervical lymph
node status, or metastatic status (7).
Although the treatment of ATC is frequently multidisci-
plinary, there is no effective cure. This may be due in part
to the rarity of this disease (and hence the lack of sufficient
research effort). Nevertheless, the inadequacy of the
current available treatment options suggests an urgent
need for development of novel treatment strategies.
Targeted molecular therapy for cancer is rapidly becom-
ing accepted as an established treatment strategy and has
shown promising results in several types of cancer (8). In
particular, preclinical and clinical studies of targeted
molecular therapy against epidermal growth factor recep-
tor (EGFR) have shown promising results against lung and
head and neck cancer (9, 10). EGFR is also frequently
overexpressed in various types of thyroid carcinomas
(11 – 16) and this overexpression has been shown to
correlate with poor prognosis in several studies (17, 18).
Recent work from our laboratory has shown that EGFR is
overexpressed in ATC tumors as well (19). Consistent with
these observations, inhibition of EGFR by using an anti-
EGFR antibody and a small-molecule inhibitor of EGFR
tyrosine kinase, AG 1478, has shown antiproliferative
effects against thyroid carcinoma cell lines in vitro (20, 21).
Despite observations that suggest EGFR as a valid
therapeutic target in thyroid cancer, this molecular targeted
approach has not been studied much in animal models.
It is well established that the activation of tumor-
expressed EGFR frequently results in increased produc-
tion of VEGF by the tumor cells (22–25). VEGF, a potent
proangiogenic molecule, is critical in establishing the
ingrowth of tumor vasculature (26). Furthermore, blockade
of EGFR has been shown to inhibit tumor-associated
angiogenesis in addition to its direct cytotoxic effects on
the tumor cells (22, 23, 27, 28). Specific inhibitors of EGFR,
such as PKI166 and ZD1839, have been shown to inhibit
both neovascularization in rat cornea model (29) and
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tumor-associated angiogenesis in an animal model of
renal cell carcinoma (30). Apoptosis of tumor-associated
endothelial cells has also been shown in response to
EGFR inhibition with small-molecule inhibitors (31).
Therefore, it has been postulated that dual blockade of
EGFR and vascular endothelial growth factor receptor
(VEGFR) will lead to greater inhibition of tumor-
associated angiogenesis compared with inhibition of
VEGFR alone (32).
In this article, we report that NVP-AEE788 (AEE788,
Novartis Pharma AG, Basel, Switzerland), a recently
described dual specific inhibitor of EGFR and VEGFR
tyrosine kinases (KDR and Flt-1; ref. 32), inhibited the
proliferation and induced apoptosis of ATC cell lines
in vitro . Furthermore, the administration of AEE788 to
athymic nude mice bearing ATC xenografts inhibited both
ATC tumor growth and tumor-associated angiogenesis.
Materials andMethods
Animals
Male athymic nude mice (ages 8 – 12 weeks) were
purchased from the animal production area of the National
Cancer Institute-Frederick Cancer Research and Develop-
ment Center (Frederick, MD). The mice were housed
and maintained in laminar flow cabinets under specific
pathogen-free conditions in facilities approved by the
American Association for Accreditation of Laboratory
Animal Care in accordance with current regulations and
standards of the U.S. Department of Agriculture, the U.S.
Department of Health and Human Services, and the NIH.
The mice were used in accordance with the Animal Care
and Use Guidelines of the University of Texas M.D.
Anderson Cancer Center (Houston, TX) under a protocol
approved by the Institutional Animal Care Use Committee.
Cell Lines and Culture Conditions
ATC cell lines C643 and K-4 were used. These cell lines
were obtained from Sai-Ching Yeung, M.D., Ph.D. (Depart-
ment of Endocrine Neoplasia and Hormonal Disorders,
University of Texas M.D. Anderson Cancer Center). The
cells were grown in RPMI 1640 supplemented with 10%
fetal bovine serum, penicillin, sodium pyruvate, and
nonessential amino acids. Adherent monolayer cultures
were maintained on plastic and incubated at 37jC in 5%
CO2 and 95% air. The cultures were free of Mycoplasma
species. The cultures were maintained no longer than
12 weeks after recovery from frozen stocks.
Reagents
AEE788 was generously provided by Novartis Pharma.
For in vitro administration, AEE788 was dissolved in DMSO
(Sigma-Aldrich Corp., St. Louis, MO) to a concentration of
20 mmol/L and further diluted to appropriate final concen-
tration in RPMI 1640 with 10% fetal bovine serum. DMSO in
the final solution did not exceed 0.1% v/v. For in vivo
testing, AEE788 was dissolved in N-methylpyrrolidone
and polyethylene glycol 300 1:9 (v/v). The AEE788
solution was prepared just before it was given to the
mice. Paclitaxel (Mead Johnson, Princeton, NJ) was
diluted 1:6 in Hank’s medium for i.p. injections. Propi-
dium iodide and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were both purchased from
Sigma-Aldrich.
Western Immunoblotting
To show that AEE788 is able to inhibit the autophos-
phorylation EGFR in vitro , Western immunoblotting was
done. All cells were incubated in serum-free medium for
24 hours. Cells were incubated with AEE788 for 1 hour at
concentrations varying from 0.01 to 20 Amol/L before
addition of EGF (40 ng/mL) for 15 minutes. The cells were
then washed with PBS and lysis buffer was added [1%
Triton X-100, 20 mmol/L Tris (pH 8.0), 137 mmol/L NaCl,
10% glycerol (v/v), 2 mmol/L EDTA, 1 mmol/L phenyl-
methylsulfonyl fluoride, 20 mmol/L aprotinin-leupeptin-
trypsin inhibitor, 2 mmol/L sodium orthovanadate]. The
cells were scraped and centrifuged to remove insoluble
proteins. The samples were diluted in sample buffer [10%
SDS, 0.5 mmol/L Tris-HCl (pH 6.8), 1 mol/L DTT, 10% (v/v)
glycerol, 1% bromophenol blue) and boiled. The proteins
(100 Ag) were resolved by PAGE and electrophoretically
transferred onto nitrocellulose membranes. The membranes
were blocked with 5% (w/v) nonfat milk in 0.1% Tween 20
(v/v) in TBS, probed with rabbit monoclonal anti-EGFR
antibody (1:2,000, Upstate Biotechnology, Inc., Lake Placid,
NY) in 1% nonfat milk, and incubated with peroxidase-
conjugated sheep anti-rabbit IgG antibody (1:2,000, Amer-
sham Life Science, Inc., Arlington Heights, IL) in 1% nonfat
milk. The blots were also probed with rabbit anti-
phosphorylated EGFR (pEGFR) antibody (Tyr1068, Cell
Signaling, Beverly, MA) diluted 1:1,000 in 1% nonfat milk
and incubated with peroxidase-conjugated sheep anti-rabbit
IgG antibody (1:2,000). Phosphorylated mitogen-activated
protein kinase (pMAPK) rabbit antibodies (Cell Signaling)
were used at a concentration of 1:3,000 with anti-rabbit IgG
at 1:2,000 as the secondary antibody. Anti-MAPK mouse
antibody (Cell Signaling) was used at 1:2,000 dilutions. Anti-
h-actin was used at a 1:1,000 concentration followed by
horseradish peroxidase–conjugated donkey anti-rabbit IgG
(1:2,000) in 1% nonfat milk. Protein bands were visualized
using the Enhanced Chemiluminescence Plus Western
blotting detection system (Amersham Life Science).
Measurement of Cell Proliferation
To test the ability of AEE788 to inhibit the proliferation of
K-4 and C643 ATC cell lines in vitro , we used a MTT-based
assay. Cells (2,000 per well) were grown in RPMI 1640
supplemented with 10% fetal bovine serum in 96-well tissue
culture plates. After 24 hours, the cells were treated with
various concentrations of AEE788 (0–6 Amol/L) in RPMI
1640 supplemented with 2% fetal bovine serum. Because of
the concern that the DMSO in AEE788 preparation may affect
the experiments, the concentrations of DMSO in all the wells
were adjusted to a common concentration. However, this
concentration of DMSO was always <2 AL/mL. To measure
the number of metabolically active cells after a 3-day incuba-
tion period, we used a MTT assay as measured by a 96-well
microtiter plate reader (MR-5000, Dynatech Laboratories,
Inc., Chantilly, VA) at an absorbance of 570 nm.
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Measurement of Cell Death
To measure cell death, K-4 and C643 cells were plated
at a density of 2  105 cells/well in 38 mm2 six-well plates
(Costar, Cambridge, MA) and maintained for 24 hours
before treatment with AEE788. After 24 hours, AEE788
was added in various concentrations in RPMI 1640
supplemented with 2% fetal bovine serum. After 48 hours
of treatment with AEE788, the extent of cell death was
determined by propidium iodide staining of hypodiploid
DNA. The concentrations of DMSO in all the wells were
adjusted to a common concentration. Furthermore, this
concentration was always kept <2 Ag/mL. The treated
cells were resuspended in a Nicoletti buffer (50 Ag/mL
propidium iodide, 0.1% sodium citrate, 0.1% Triton X-100)
for 20 minutes at 4jC. Cells were then analyzed by flow
cytometry and the sub-G0/G1 fraction was measured.
Immunohistochemistry on MurineTumorTissue Sec-
tions
Immunohistochemistry was done with the following
antibodies: rabbit anti-pEGFR (Tyr1068), rabbit anti-EGFR
(Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-
pMAPK, rabbit anti-MAPK, rabbit anti-phosphorylated
VEGFR-2 (pVEGFR-2; Tyr1045, Santa Cruz Biotechnology),
and rat anti-mouse CD31-platelet/endothelial cell adhesion
molecule 1 (PharMingen, San Diego, CA). For EGFR
staining, paraffin-embedded sections were first dewaxed
in xylene. Excess xylene was removed by washing the
slides in ethanol. After treating the tissue with pepsin for 20
minutes at 37jC, the slides were washed thrice with PBS.
Endogenous blocking was done with 3% H2O2 followed by
protein blocking using 5% horse serum with 1% goat serum
(protein-blocking solution). After washing the slides in
PBS, the primary antibody (1:200 dilution) was added for
18 hours at 4jC. The slides were then washed with PBS
thrice, blocked again with protein-blocking solution for
1 hour, and incubated with horseradish peroxidase–
conjugated anti-rabbit antibody at 1:200 dilutions for 1 hour
at room temperature. The slides were washed again in PBS
thrice and then incubated with 3,3V-diaminobenzidine
tetrahydrochloride (DAB) for 10 minutes. After the excess
DAB was washed off, counterstaining was done with Gill’s
No. 3 hematoxylin.
For staining with antibodies against pEGFR, pMAPK,
total MAPK, pVEGFR-2, and CD31-platelet/endothelial
cell adhesion molecule 1, frozen tumors were sectioned
(8–10 mm thick), mounted on positively charged Super-
frost slides (Fisher Scientific, Houston, TX), air dried for 30
minutes, and fixed in cold acetone for 10 minutes. The
slides were washed thrice with PBS (pH 7.5), blocked for 20
minutes at room temperature in PBS supplemented with
1% normal goat serum and 5% normal horse serum
(protein-blocking solution), and incubated with primary
antibody (1:50 dilution for pEGFR, pMAPK, and total
MAPK antibodies, 1:400 dilution for pVEGFR-2, and 1:800
dilution for CD31-platelet/endothelial cell adhesion mole-
cule 1 antibody) for 18 hours at 4jC. The samples were then
washed thrice for 3 minutes and blocked with protein-
blocking solution for 10 minutes. For pEGFR, pMAPK, total
MAPK, and pVEGFR-2, the samples were then incubated
with Alexa Fluor 594–conjugated goat anti-rabbit IgG at
1:400 (Molecular Probes, Eugene, OR) for 1 hour at room
temperature in the dark. Samples were again washed thrice
for 5 minutes and then counterstained with 300 Ag/mL
Hoechst stain for 1 to 2 minutes at room temperature. The
slides were again washed and then mounted using propyl
gallate. CD31-platelet/endothelial cell adhesion molecule 1
staining was visualized using DAB chromogen. For this
purpose, the sections were washed with PBS and incubated
with blocking solution for 5 minutes. The sections were then
incubated with anti-rat secondary antibody conjugated
with horseradish peroxidase (1:800 dilution) for 1 hour at
room temperature. The slides were washed again in PBS
thrice and then incubated with DAB for 10 minutes. After
the excess DAB was washed off, counterstaining was done
with Gill’s No. 3 hematoxylin.
To assess the degree of intratumoral apoptosis, terminal
deoxynucleotidyl transferase–mediated dUTP nick end
labeling (TUNEL) staining was done using an apoptosis
detection kit (Promega, Madison, WI) with the following
modifications: tissues were fixed with 4% paraformalde-
hyde (methanol free) for 10 minutes at room temperature,
washed twice with PBS for 5 minutes, and then incubated
with 0.2% Triton X-100 for 15 minutes at room temperature.
Then, the tissue sections were incubated with reaction
buffer containing 44 AL equilibration buffer, 5 AL nucleo-
tide mix, and 1 AL terminal deoxynucleotidyl transferase at
37jC for 1 hour. The reaction was terminated by immersing
the samples in 2 SCC for 15 minutes. The samples were
then washed thrice for 5 minutes with PBS to remove
unincorporated fluorescein-dUTP.
Immunofluorescence microscopy was done using a Zeiss
Axioplan2 microscope (Carl Zeiss, Thornwood, NY)
equipped with a 100 W HBO mercury bulb and filter sets
(Chroma, Inc., Brattleboro, VT) to individually capture red
and blue fluorescent images. Images were captured using a
C5810 Hamamatsu color chilled three-chip charge-coupled
device camera (Hamamatsu, Japan) and digitized using
Optimas imaging software (Silver Spring, MD). To image
the DAB-stained paraffin section, the stained sections were
examined in a Microphot-FX microscope (Nikon, Melville,
NY) equipped with a three-chip charge-coupled device
color video camera (Model DXC990, Sony Corp., Tokyo,
Japan).
For quantitative analysis of TUNEL staining, the labeled
cells were counted in five random 0.159 mm2 fields (100
magnification) per slide from a total of five slides per study
group. To quantify microvessel density (MVD), the labeled
endothelial cells were counted from five random 0.159 mm2
fields (100 magnification) per slide from a total of five
slides per study group.
The photomontages were prepared using Photoshop
software (Adobe Systems, Inc., San Jose, CA).
In vivo s.c. Xenografts
The K-4 cell line was selected for this part of the
study because of its high tumorigenicity in nude mice.
K-4 cells were harvested from subconfluent cultures by
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trypsinization and washed. K-4 cells (2.5  106) were
injected s.c. into each mouse on the right flank under direct
visualization using a 30 gauge needle. The tumors were
allowed to develop during the following 7 days. After the
development of palpable tumors, the mice were random-
ized into four groups of 10 mice per each group, and the
drugs were given as follows: (a) AEE788 via p.o. gavages
at 50 mg/kg thrice weekly, (b) paclitaxel via i.p. injection at
200 Ag/injection once weekly, (c) both AEE788 via p.o.
gavages at 50 mg/kg thrice weekly and paclitaxel via i.p.
injection at 200 Ag/injection once weekly, and (d) 250 AL
N-methylpyrrolidone and polyethylene glycol 300 1:9 (v/v)
given via p.o. gavage and PBS given i.p. as placebo.
Twice weekly, the mice were weighed and tumor sizes
were measured. The volumes of the tumors were deter-
mined using the formula: V = (p/6)WL2, where W and L
represent measurements in two dimensions, with L being
the smaller dimension. Our animal protocol required that
the mice be sacrificed if they became moribund or lost
>20% of their weight. However, all the mice survived until
the end of the 6-week treatment period without weight loss
of >20% or morbidity. Therefore, all the mice were
sacrificed at the end of the treatment period. When the
mice were killed at the end of 6-week treatment period,
AEE788 and paclitaxel were given 2 hours before the
sacrifice.
For immunohistochemical and routine H&E staining, one
part of the tumor was fixed in formalin and embedded in
paraffin. Another part was embedded in OCT compound
(Miles, Inc., Elkhart, IN), rapidly frozen in liquid nitrogen,
and stored at 80jC.
Statistical Analysis
The nonparametric Wilcoxon rank-sum test was used to
assess differences in mouse tumor volume between each
treatment group and the control group. To check for a
difference between the combination treatment and the
single-agent groups, we ran a repeated-measures regres-
sion model with treatment, time, and treatment by time
interaction to compare the tumor volumes observed for the
group receiving AEE788 plus paclitaxel with the group
receiving paclitaxel alone. This methodology was also used
to compare tumor volumes in the group receiving AEE788
plus paclitaxel to the group receiving AEE788 alone.
TUNEL staining results and MVD counts were compared
by a two-sample Student’s t test. Best-fit curves were
generated for the MTT and propidium iodide assays and
used to determine the concentration at which 50% of the
drug effect (IC50) were exhibited.
Results
AEE788 Inhibits EGFRAutophosphorylation In vitro
We first examined the ability of AEE788 to inhibit EGFR
autophosphorylation (Fig. 1). Serum-starved K-4 cells did
not show EGFR autophosphorylation when examined
by Western blotting. However, the addition of EGF to
the serum-free medium for 15 minutes resulted in the
phosphorylation of both EGFR and MAPK. AEE788
Figure 1. AEE788 inhibits phosphorylation of EGFR and MAPK in vitro .
ATC cell line K-4 was serum starved for 24 h and then incubated with
increasing concentrations of AEE788 (0.01–20 Amol/L) for 1 h before the
addition of 40 ng/mL recombinant EGF for 15 min. Cells were then
harvested and Western blotting was done.
Figure 2. A, AEE788 inhibits the proliferation of ATC cell lines in vitro .
ATC cell lines K-4 and C643 were plated on 96-well plates at 2,000 cells
per well. Twenty-four hours after plating, the cells were treated with
increasing concentrations of AEE788 (0–6 Amol/L) for 72 h. The inhibitory
effect of AEE788 was then measured using a MTT assay. B, AEE788
induces the apoptosis of ATC cell lines in vitro . ATC cell lines K-4 and
C643 were plated on six-well plates at 1  105 cells per well. Twenty-four
hours after plating, the cells were treated with AEE788 (0–30 Amol/L) for
48 h. Cells were then collected, stained with propidium iodide, and
analyzed by flow cytometry for apoptotic fraction.
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was able to inhibit the EGF-induced autophosphorylation
of EGFR at 0.1 Amol/L. At a concentration of 1 Amol/L,
EGF-induced phosphorylation of MAPK was also
inhibited.
AEE788 Inhibits Proliferationof ATCCell Lines In vitro
After having shown that AEE788 is able to inhibit
the activation of tumor-expressed EGFR, we examined
the antiproliferative property of this agent on ATC cell
lines. ATC cell lines C643 and K-4 were incubated
with increasing concentrations (0–6 Amol/L) of AEE788
in RPMI 1640 supplemented with 2% serum. After 72
hours, the degree of proliferation was determined using a
MTT assay (Fig. 2A). Our previous experiences with these
cell lines showed that K-4 and C643 display approximately
three cell doublings within the 72-hour period (data not
shown). The proliferation of both C643 and K-4 cells was
inhibited by AEE788 in a dose-dependent manner. The IC50
was determined to be 2.13 Amol/L for C643 and 0.88 Amol/L
for K-4 cell line. The proliferation of K-4 and C643 cell
lines was decreased by f40% and 30%, respectively, at the
IC50. These MTT data were also confirmed by counting the
cells at 72 hours after treatment with AEE788 (data not
shown).
AEE788 Induces Apoptosis of ATCCell Lines In vitro
To examine the proapoptotic effects of AEE788, the
K-4 and C643 cell lines were treated with varying
concentrations of AEE for 48 hours. The degree of
apoptosis was then measured using propidium iodide
staining method (Fig. 2B). AEE788 induced apoptosis in
ATC cell lines in a dose-dependent manner. The K-4 cell
line was more sensitive than C643 to induction of apoptosis
by AEE788. The IC50s for induction of apoptosis were
found to be 12 Amol/L for C643 and 17 Amol/L for K-4.
However, the magnitude of apoptosis at the IC50 was
f35% for both cell lines and the maximal apoptosis of 70%
required relatively high concentration of >20 Amol/L
AEE788.
AEE788 Inhibits ATC Xenograft Growth In vivo
With respect to the xenografts assay, both AEE788 and
paclitaxel were able to inhibit the growth of ATC
xenografts generated with K-4 cell line in nude mice.
However, the highest growth inhibition was achieved by
the coadministration of AEE788 and paclitaxel (Fig. 3). At
the end of the 42-day treatment period, the mice treated
with paclitaxel, AEE788, and AEE788 plus paclitaxel
showed 44%, 58%, and 69% decreases, respectively, in the
mean estimated tumor volume compared with the control
group (P < 0.05). The difference in tumor volume for the
treatment groups was statistically significant compared
with the control group starting on treatment day 12. The
mean tumor volume of the group receiving the combina-
tion treatment was also compared with that of the groups
receiving AEE788 alone or paclitaxel alone. The difference
in mean tumor volumes of the paclitaxel treatment group
compared with combination treatment group became
statistically significant after treatment day 23 (P < 0.05).
However, there were no statistically significant differences
in the mean tumor volume between the mice treated with
AEE788 alone and those treated with both AEE788 and
paclitaxel.
AEE788 was well tolerated by the animals without
substantial adverse effects. The weights of the animals
remained constant throughout the treatment period (data
not shown) and none of the animals required sacrifice
before the end of the study.
AEE788 Inhibits EGFRAutophosphorylation and Indu-
ces Apoptosis of K-4 Tumor Cells In vivo
To show in vivo inhibition of EGFR autophosphorylation
by AEE788, immunohistochemical staining was done using
antibodies specific to EGFR and tyrosine-phosphorylated
EGFR (Fig. 4). Tumors from all the study groups
showed similar levels of total EGFR expression, whereas
only tumors from control mice or mice treated with
paclitaxel stained positive for pEGFR. To determine
whether the blockade of EGFR down-regulated any
elements of downstream signaling pathways, tumors
from the study groups were stained with antibodies
specific to MAPK and pMAPK (Fig. 4). Although the
level of MAPK expression was similar throughout the
study groups, pMAPK staining was absent in tumors of
mice treated with AEE788 alone or in combination with
paclitaxel.
To assess the degree of intratumoral apoptosis, the tumor
sections were stained using the TUNEL method (Fig. 5).
The mean numbers of apoptotic cells per unit area in the
tumors of control mice and the mice treated with paclitaxel
were 13.4 and 26.9, respectively (P < 0.05). However,
treatment with either AEE788 alone or in combination with
paclitaxel significantly increased the mean numbers of
apoptotic cells per unit area to 78.1 and 102.8, respectively
(Table 1; P< 0.001).
Figure 3. AEE788 inhibits the growth of ATC xenografts in nude mice.
K-4 cells were injected into the right flank of nude mice. After tumor
development, the mice (n = 10) were treated with p.o. gavage of AEE788
50 mg/kg thrice weekly, paclitaxel given via i.p. injection at 200 Ag/
injection once weekly, or both AEE788 50 mg/kg thrice weekly and
paclitaxel via i.p. injection at 200 Ag/injection once weekly. The control
mice received N-methylpyrrolidone and polyethylene glycol 300 1:9 (v/v),
which was used as the solvent for the AEE788. Points, mean tumor size
measured twice weekly; bars, SE.
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AEE788 Inhibits Endothelial Cell ^ Expressed EGFR
and VEGFR Autophosphorylation and Inhibits Tumor-
Associated Angiogenesis
To determine the effect of AEE788 on endothelial cell–
expressed EGFR and VEGFR-2, CD31/pEGFR and CD31/
pVEGFR-2 double labeling techniques were used (Fig. 5).
K-4 tumors from control mice or mice treated with paclitaxel
showed strong colabeling of fluorescent red CD31 staining
specific for endothelial cells with fluorescent green staining
of pVEGFR-2. Likewise, colabeling of fluorescent red for
endothelial cells with fluorescent green of pEGFR staining
was shown in tumors from control mice or mice treated
with paclitaxel. In contrast, autophosphorylation of endo-
thelial cell–expressed EGFR and VEGFR-2 was significantly
suppressed in K-4 tumors of mice treated with AEE788
alone or in combination with paclitaxel.
Figure 4. Immunohistochemical analysis. After 42 d of treatment with AEE788, paclitaxel, or AEE788 + paclitaxel, K-4 tumors were sectioned and
stained for EGFR, MAPK, pEGFR, and pMAPK as described in Materials and Methods. Treatment with AEE788, alone or in combination with paclitaxel,
inhibited the phosphorylation of EGFR and MAPK. Levels of expression for these proteins were similar throughout the study groups. Original
magnification, 100.
Table 1. Quantitative analysis of TUNEL and CD31 immunohistochemical staining
Control Paclitaxel AEE788 AEE788 + paclitaxel
TUNEL* (mean F SD) 13.4 F 9.2 26.9 F 18.4c 78.1 F 55.9c 102.8 F 55.7c
MVDb (mean F SD) 46.7 F 28.1 40.5 F 20.4x 6.7 F 7.8k 4.0 F 3.5k
*TUNEL staining was quantitated by counting the number of positively stained cells from five random 0.159 mm2 field (100 magnification) per slide from a
total of five slides per treatment group.
cP < 0.05 compared with the control group (Student’s t test).
bMVD was quantitated by counting the number of positively stained cells for CD31 from five random 0.159 mm2 field (100 magnification) per slide from a
total of five slides per treatment group.
xP = 0.381 compared with the control group (Student’s t test).
kP < 0.001 compared with the control group (Student’s t test).
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Lastly, MVD was determined by staining tumor sections
for CD31-specific antibodies (Fig. 5). Treatment with
paclitaxel did not affect the tumor MVD significantly
compared with the control group. However, treatment
with AEE788 alone or in combination with paclitaxel
resulted in >80% inhibition of tumor-associated angiogen-
esis (Table 1; P < 0.001).
Discussion
The overexpression of EGFR has been implicated in the
pathogenesis and progression of many types of cancer.
In the normal thyroid gland, EGFR expression is
detectable albeit at a low level (11, 12, 33, 34). Compared
with the basal level of EGFR expression in the normal
thyroid gland, EGFR expression is significantly higher in
thyroid carcinoma cell lines (34) and is overexpressed in up
to 90% of follicular and papillary thyroid carcinoma
specimens (12). The status of EGFR expression in ATC
has not yet been well characterized, although preliminary
work from this laboratory has shown EGFR to be highly
expressed in most archived ATC paraffin-embedded speci-
mens (19). Furthermore, the status of EGFR expression is a
poor prognostic factor in thyroid carcinoma patients.
Multivariate analyses in studies by Akslen and Varhaug
(17) and Chen et al. (18) have shown that EGFR over-
expression was associated with a high frequency of lymph
node metastasis and larger tumors in patients with well-
differentiated thyroid carcinomas.
The therapeutic potential of EGFR inhibition in thyroid
carcinoma has been shown in several in vitro studies
(20, 21, 35). Gabler et al. (20) showed that a monoclonal
antibody against EGFR inhibited the in vitro proliferation of
papillary thyroid carcinoma cell lines. More importantly,
Yin et al. (35) showed that inhibition of EGFR tyrosine
kinase with apigenin, a flavonoid compound, resulted in
apoptosis of ATC cell lines in vitro . Despite the evidence
that EGFR inhibition may be a valid therapeutic strategy
against ATC, only few studies that examined the in vivo
effects of EGFR inhibition on thyroid carcinoma have not
been reported. In this report, we showed that the blockade
of EGFR signaling pathway using AEE788, a novel, dual
specific inhibitor of EGFR and VEGFR tyrosine kinases,
resulted in in vitro inhibition of proliferation and induction
Figure 5. Immunohistochemical analysis. Tissue sections were immunostained for TUNEL (fluorescent green ) to determine the degree of in vivo
apoptosis, for CD31 (DAB staining) to quantify MVD, and for double label of CD31 (fluorescent red) with pEGFR (fluorescent green) or CD31 (fluorescent
red) with pVEGFR-2 (fluorescent green ). K-4 tumors from mice treated with AEE788 alone or in combination with paclitaxel showed significant increase in
apoptosis and decrease in MVD (P < 0.05). Treatment with AEE788 also inhibited the phosphorylation of EGFR and VEGFR-2 on tumor endothelium.
TUNEL and CD31 stain: original magnification, 100; CD31/pEGFR and CD31/pVEGFR-2: original magnification, 400.
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of apoptosis of ATC cells. The inhibition of EGFR resulted
in down-regulation of downstream signaling pathways as
evidenced by the in vitro and in vivo inhibition of MAPK
activation. These effects were maintained in vivo where
AEE788 induced apoptosis of the tumor cells and signifi-
cantly inhibited the growth of ATC xenografts in nude
mice.
Administration of AEE788 also significantly decreased
tumor-associated angiogenesis. The decrease in MVD in
tumors of mice treated AEE788 can be attributed to several
mechanisms. First, it has been shown previously in several
organ systems and tumor types that activation of EGFR
signaling pathway results in up-regulation of VEGF pro-
duction by the target cells (22, 27, 36). Conversely, EGFR
blockade using EGFR monoclonal antibody C225 has been
shown to down-regulate the production of VEGF by tumor
cells and decreased the MVD in nude mice xenografts of
transitional cell carcinoma (27), renal cell carcinoma (28),
and colorectal carcinoma (37). Similarly, we have found that
AEE788 decreases the in vitro VEGF production by ATC cell
lines.4 AEE788 was able to inhibit tumor-expressed EGFR
and this may partly account for the decreased MVD in
tumors of mice treated with this compound.
The decreased angiogenesis in tumors of mice treated
with AEE788 can also be attributed to the inhibition of
endothelial cell–expressed EGFR. As shown by immuno-
fluorescent microscopy, the administration of AEE788
efficiently inhibited the autophosphorylation of EGFR on
the tumor endothelium. Recent results have suggested that
blockade of endothelial cell–expressed EGFR leads to arrest
of human umbilical vascular endothelial cells in G1 phase
and inhibits endothelial cell proliferation in vivo (29, 30). In
a study by Hirata et al. (29), gefinitib, an inhibitor of EGFR
tyrosine kinase, completely inhibited neoangiogenesis
in vivo in rat cornea model of angiogenesis. Furthermore,
a recent preclinical study showed that blockade of
endothelial cell–expressed EGFR using PKI166 resulted in
endothelial cell apoptosis in pancreatic carcinoma (31).
Lastly, the antiangiogenic property of AEE788 can be
attributed to its ability to inhibit endothelial cell –
expressed VEGFR tyrosine kinase. The critical need for
VEGFR activation in endothelial cell proliferation is well
documented (38, 39). Furthermore, antiangiogenic strate-
gies using a monoclonal antibody against VEGF have
shown promising results in vivo against nude mice
xenografts of various thyroid carcinomas, including ATC
(40, 41). In our study, we showed via immunofluorescent
microscopy that the administration of AEE788 efficiently
inhibited the autophosphorylation of VEGFR-2 on tumor
endothelium.
The concept of dual inhibition of EGFR and VEGFR is not
new and has been evaluated in animal models of colon (37),
gastric (42), and pancreatic carcinomas (43). However,
these studies used the administration of two agents
targeting each receptor separately. The major advantages of
AEE788 are that it is able as a single agent to efficiently
block of both EGFR and VEGFR tyrosine kinases and that it
is orally given and well tolerated. Although the double
specificity of AEE788 may raise the concern of possible,
nonspecific interaction of this compound with other
tyrosine kinases, in vitro studies by Traxler et al. have
confirmed the affinity of the inhibitor to be highly selective
for EGFR and VEGFR tyrosine kinases (32).
In this study, the in vivo antitumor efficacy of AEE788 was
evaluated as a single agent therapy as well as in combination
with paclitaxel. EGFR blockade has shown synergistic effect
on tumor cells when combined with radiotherapy and other
DNA damaging agents, such as irinotecan (44, 45).
Although the animals treated with AEE788 and paclitaxel
had statistically significant reduction in tumor volume
compared with those that received paclitaxel alone, similar
statistical significance could not be shown for mice treated
with AEE788 alone when compared with the combination
treatment group. However, toward the end of the
treatment period, there was a separation of tumor growth
curve between mice treated with AEE788 alone and those
treated in combination with paclitaxel. With longer study
period, this separation most likely would have reached
statistical significance. Given the significant antitumor
activity of AEE788 against ATC when given in combination
with paclitaxel, its role in multimodal therapy seems
promising and remains to be further elucidated.
In conclusion, ATC is a highly aggressive disease with
poor prognosis that warrants the development of novel
treatment strategies. AEE788, an orally given inhibitor of
EGFR and VEGFR kinases, has shown significant antitumor
activity against ATC cell lines in vitro and against ATC
xenografts in vivo in nude mice. In addition, AEE788
efficiently inhibited tumor-associated angiogenesis and
decreased the intratumoral MVD. The inhibition of overall
tumor growth in mice treated with AEE788 is most likely
the result of its direct cytotoxicity on the tumor cells as well
as the suppression of tumor-associated angiogenesis.
Considering the fact that curative options seldom exist for
patients with ATC, concurrent inhibition of EGFR and
VEGFR tyrosine kinases seems to be a valid and promising
anticancer strategy for these patients.
References
1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501–11.
2. Pasieka JL. Anaplastic thyroid carcinoma. Curr Opin Oncol
2003;15:78–83.
3. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for
thyroid carcinoma. A population-based study of 15,698 cases from the
Surveillance, Epidemiology and End Results (SEERS) program 1973-1991.
Cancer 1997;79:564–73.
4. Tan RK, Finley RK III, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP.
Anaplastic carcinomas of the thyroid: a 24-year experience. Head Neck
1995;17:41–7.
5. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and thera-
peutic approaches. Thyroid 1998;8:715–26.
6. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma:
a 50-year experience at a single institution. Surgery 2001;130:1028–34.4 Unpublished data.
Molecular Cancer Therapeutics 639
Mol Cancer Ther 2005;4(4). April 2005
Research. 
on March 16, 2018. © 2005 American Association for Cancermct.aacrjournals.org Downloaded from 
7. American Joint Committee on Cancer. In: Greene FL, Page DL, Fleming ID,
et al., editors. American Joint Committee on Cancer manual for staging
cancer. 5th ed. Philadelphia: Lippincott-Raven; 1997.
8. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in
cancer therapy. Expert Opin Investig Drugs 2002;11:837–49.
9. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in
head and neck cancer. Head Neck 2003;25:67–73.
10. Baselga J, Hammond LA. HER-targeted tyrosine-kinase inhibitors.
Oncology 2002;63:6–16.
11. Duh QY, Gum ET, Gerend PL, Raper SE, Clark OH. Epidermal growth
factor receptors in normal and neoplastic thyroid tissues. Surgery
1985;98:1000–7.
12. Makinen T, Pekonen F, Franssila K, Lamberg BA. Receptors for
epidermal growth factor and thyrotropin in thyroid carcinoma. Acta
Endocrinol (Copenh) 1988;117:45–50.
13. Duh QY, Siperstein AE, Miller RA, Sancho JJ, Demeure MJ, Clark OH.
Epidermal growth factor receptors and adenylate cyclase activity in human
thyroid tissue. World J Surg 1990;14:410–7.
14. Lemoine NR, Hughes CM, Gullick WJ, Brown CL, Wynford-Thomas D.
Abnormalities of the EGF receptor system in human thyroid neoplasia. Int J
Cancer 1991;49:558–61.
15. Gorgoulis V, Aninos D, Priftis C, et al. Expression of epidermal growth
factor, transforming growth factor-a and epidermal growth factor receptor
in thyroid tumors. In Vivo 1992;6:291–6.
16. Song B. Immunohistochemical demonstration of epidermal growth
factor receptors and ceruloplasmin in thyroid disease. Acta Pathol Jpn
1991;41:333–43.
17. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in
papillary thyroid carcinoma: presence of epidermal growth factor receptor,
c-erbB-3 protein, estrogen receptor related protein, p21-ras protein, and
proliferation indicators in relation to tumor recurrences and patient
survival. Cancer 1995;76:1643–54.
18. Chen BK, Ohtsuki Y, Furihata M, et al. Co-overexpression of p53
protein and epidermal growth factor receptor in human papillary thyroid
carcinomas correlates with lymph node metastasis, tumor size and
clinicopathologic stage. Int J Oncol 1999;15:893–8.
19. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor
receptor (EGF-R) is overexpressed in anaplastic thyroid cancer, and the
EGF-R inhibitor gefinitib (‘‘Iressa’’, ZD1839) inhibits the growth of
anaplastic thyroid cancer. Clin Cancer Res 2004;10:8594–602.
20. Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R. Growth
inhibition of human papillary thyroid carcinoma cells and multicellular
spheroids byanti-EGF-receptor antibody.Anticancer Res1997;17:3157–9.
21. Bergstrom JD, Westermark B, Heldin NE. Epidermal growth factor
receptor signaling activates met in human anaplastic thyroid carcinoma
cells. Exp Cell Res 2000;259:293–9.
22. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY.
Epidermal growth factor stimulates vascular endothelial growth factor
production by human malignant glioma cells: a model of glioblastoma
multiforme pathophysiology. Mol Biol Cell 1993;4:121–33.
23. Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis
by the antiepidermal growth factor receptor antibody ImClone C225 in
androgen-independent prostate cancer growing orthotopically in nude
mice. Clin Cancer Res 2002;8:1253–64.
24. Riedel F, Gotte K, Li M, Hormann K, Grandis JR. EGFR antisense
treatment of human HNSCC cell lines down-regulate VEGF expression and
endothelial cell migration. Int J Oncol 2002;21:11–6.
25. Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth
factor modulates the expression of vascular endothelial growth factor in
the human prostate. J Androl 2001;22:432–43.
26. Folkman J. Angiogenesis in cancer, vasculature, rheumatoid, and
other disease. Nat Med 1995;1:27–31.
27. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor
receptor antibody C225 inhibits angiogenesis in human transitional cell
carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:
257–65.
28. Kedar D, Baker CH, Killion JJ, Dinney CP, Fidler IJ. Blockade of the
epidermal growth factor receptor signaling inhibits angiogenesis leading to
regression of human renal cell carcinoma growing orthotopically in nude
mice. Clin Cancer Res 2002;8:3592–600.
29. Hirata A, Uehara H, Izumi K, Naito S, Kuwano M, Ono M. Direct
inhibition of EGF receptor activation in vascular endothelial cells by
gefinitib (Iressa, ZD1839). Cancer Sci 2004;95:614–8.
30. Asakuma J, Sumitomo M, Asano T, Asano T, Hayakawa M.
Modulation of tumor growth and tumor induced angiogenesis after
epidermal growth factor receptor inhibition by ZD1839 in renal cell
carcinoma. J Urol 2004;171:897–902.
31. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the
epidermal growth factor receptor signaling by a novel tyrosine kinase
inhibitor leads to apoptosis of endothelial cells and therapy of human
pancreatic carcinoma. Cancer Res 2000;60:2926–35.
32. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family
epidermal growth factor receptor/ErbB2 and vascular endothelial growth
factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic
activity. Cancer Res 2004;64:4931–41.
33. Kanamori A, Abe Y, Yajima Y, Manabe Y, Ito K. Epidermal growth
factor receptors in plasma membranes of normal and diseased human
thyroid glands. J Clin Endocrinol Metab 1989;68:899–903.
34. Miyamoto M, Sugawa H, Mori T, Hase K, Kuma K, Imura H. Epidermal
growth factor receptors on cultured neoplastic human thyroid cells and
effects of epidermal growth factor and thyroid-stimulating hormone on
their growth. Cancer Res 1988;48:3652–6.
35. Yin F, Giuliano AE, Van Herle AJ. Signal pathways involved in
apigenin inhibition of growth and induction of apoptosis of human
anaplastic thyroid cancer cells (ARO). Anticancer Res 1999;19:
4297–303.
36. Moller B, Rasmussen C, Lindblom B, Olovsson M. Expression of
the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in
normal human endometrium during the menstrual cycle. Mol Hum Reprod
2001;7:65–72.
37. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor
activity of anti-epidermal growth factor receptor C225 monoclonal
antibody in combination with vascular endothelial growth factor antisense
oligonucleotides in human GEO colon cancer cells. Clin Cancer Res
2000;6:3739–47.
38. Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in
tumors angiogenesis: molecular facts and therapeutic opportunities.
Cancer Metastasis Rev 1998;17:241–8.
39. Folkman J. Clinical applications of research on angiogenesis. N Engl J
Med 1995;333:1757–63.
40. Bauer AJ, Terell R, Doniparthi NK, et al. Vascular endothelial growth
factor monoclonal antibody inhibits growth of anaplastic thyroid cancer
xenografts in nude mice. Thyroid 2002;12:953–61.
41. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C.
Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth
of poorly differentiated thyroid carcinoma: an animal study. Endocrinology
2004;145:1031–8.
42. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-
vascular endothelial growth factor receptor and anti-epidermal growth
factor receptor therapies on the growth of gastric cancer in a nude mouse
model. Eur J Cancer 2002;38:1133–40.
43. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial
growth factor receptor and epidermal growth factor receptor signaling for
therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:
1996–2003.
44. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW,
Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth
factor receptor monoclonal antibody IMC-225 in combination with
irinotecan (CPT-11) against human colorectal tumor xenograft. Cancer
Res 2002;8:994–1003.
45. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of
sequential treatment with topotecan anti-epidermal growth factor receptor
monoclonal antibody C225. Clin Cancer Res 1999;5:909–16.
EGFR and VEGFR Inhibition in Anaplastic Thyroid Carcinoma640
Mol Cancer Ther 2005;4(4). April 2005
Research. 
on March 16, 2018. © 2005 American Association for Cancermct.aacrjournals.org Downloaded from 
2005;4:632-640. Mol Cancer Ther 
  
Seungwon Kim, Bradley A. Schiff, Orhan G. Yigitbasi, et al. 
  
with AEE788
Targeted molecular therapy of anaplastic thyroid carcinoma
  
Updated version
  
 http://mct.aacrjournals.org/content/4/4/632
Access the most recent version of this article at:
  
  
  
  
  
Cited articles
  
 http://mct.aacrjournals.org/content/4/4/632.full#ref-list-1
This article cites 42 articles, 12 of which you can access for free at:
  
Citing articles
  
 http://mct.aacrjournals.org/content/4/4/632.full#related-urls
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
Rightslink site. 
(CCC)
Click on "Request Permissions" which will take you to the Copyright Clearance Center's
.http://mct.aacrjournals.org/content/4/4/632
To request permission to re-use all or part of this article, use this link
Research. 
on March 16, 2018. © 2005 American Association for Cancermct.aacrjournals.org Downloaded from 
